Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer

Lorraine Tafra; Zandra Cheng; Joseph Uddo; Mary B. Lobrano; William Stein; Wendie A. Berg; Edward Levine; Irving N. Weinberg; Deepa Narayanan; Eric Ross; David Beylin; Stephen Yarnall; Rochelle Keen; Kristen Sawyer; Jack Van Geffen; Rita L. Freimanis; Edward Staab; Lee P. Adler; Judy Lovelace; Perry Shen; John Stewart; Sergei Dolinsky

doi:10.1016/j.amjsurg.2005.06.029

Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer

Lorraine Tafra, Zandra Cheng, Joseph Uddo, Mary B. Lobrano, William Stein, Wendie A. Berg, Edward Levine, Irving N. Weinberg, Deepa Narayanan, Eric Ross, David Beylin, Stephen Yarnall, Rochelle Keen, Kristen Sawyer, Jack Van Geffen, Rita L. Freimanis, Edward Staab, Lee P. Adler, Judy Lovelace, Perry ShenJohn Stewart, Sergei Dolinsky

Cancer Prevention and Control (CPC)

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Abstract

Background: High-resolution positron-emission mammography (PEM) is a new device, which allows the imaging of breast tissue. A prospective study was performed to assess the accuracy of PEM in newly diagnosed breast cancer patients. Methods: In a prospective multicenter study, 44 women with confirmed breast cancers were imaged with a high-resolution PEM scanner (Naviscan PET Systems, Rockville, MD) with 18F-fluorodeoxyglucose. The images were blindly evaluated and were compared with final pathology. Results: The majority of the index lesions were seen on PEM (89%, 39/44). PEM detected 4 of 5 incidental breast cancers, 3 of which were not seen by any other imaging modalities. Of 19 patients undergoing breast-conserving surgery, PEM correctly predicted 6 of 8 (75%) patients with positive margins and 100% (11/11) with negative margins. Conclusion: The current PEM device shows promise in detecting breast malignancies and may assist in the planning of adequate partial mastectomy procedures to better ensure negative margins.

Original language	English
Pages (from-to)	628-632
Number of pages	5
Journal	American Journal of Surgery
Volume	190
Issue number	4
DOIs	https://doi.org/10.1016/j.amjsurg.2005.06.029
State	Published - Oct 2005

Keywords

Adult
Aged
Aged, 80 and over
Breast Neoplasms/diagnostic imaging
Female
Fluorodeoxyglucose F18
Humans
Mammography/methods
Middle Aged
Pilot Projects
Positron-Emission Tomography/methods
Predictive Value of Tests
Prospective Studies
Radiopharmaceuticals
Single-Blind Method

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.amjsurg.2005.06.029

Cite this

Tafra, L., Cheng, Z., Uddo, J., Lobrano, M. B., Stein, W., Berg, W. A., Levine, E., Weinberg, I. N., Narayanan, D., Ross, E., Beylin, D., Yarnall, S., Keen, R., Sawyer, K., Van Geffen, J., Freimanis, R. L., Staab, E., Adler, L. P., Lovelace, J., ... Dolinsky, S. (2005). Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer. American Journal of Surgery, 190(4), 628-632. https://doi.org/10.1016/j.amjsurg.2005.06.029

@article{8c704abc6db54320b2c6544209ca4a38,

title = "Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer",

abstract = "Background: High-resolution positron-emission mammography (PEM) is a new device, which allows the imaging of breast tissue. A prospective study was performed to assess the accuracy of PEM in newly diagnosed breast cancer patients. Methods: In a prospective multicenter study, 44 women with confirmed breast cancers were imaged with a high-resolution PEM scanner (Naviscan PET Systems, Rockville, MD) with 18F-fluorodeoxyglucose. The images were blindly evaluated and were compared with final pathology. Results: The majority of the index lesions were seen on PEM (89%, 39/44). PEM detected 4 of 5 incidental breast cancers, 3 of which were not seen by any other imaging modalities. Of 19 patients undergoing breast-conserving surgery, PEM correctly predicted 6 of 8 (75%) patients with positive margins and 100% (11/11) with negative margins. Conclusion: The current PEM device shows promise in detecting breast malignancies and may assist in the planning of adequate partial mastectomy procedures to better ensure negative margins.",

keywords = "Adult, Aged, Aged, 80 and over, Breast Neoplasms/diagnostic imaging, Female, Fluorodeoxyglucose F18, Humans, Mammography/methods, Middle Aged, Pilot Projects, Positron-Emission Tomography/methods, Predictive Value of Tests, Prospective Studies, Radiopharmaceuticals, Single-Blind Method",

author = "Lorraine Tafra and Zandra Cheng and Joseph Uddo and Lobrano, {Mary B.} and William Stein and Berg, {Wendie A.} and Edward Levine and Weinberg, {Irving N.} and Deepa Narayanan and Eric Ross and David Beylin and Stephen Yarnall and Rochelle Keen and Kristen Sawyer and {Van Geffen}, Jack and Freimanis, {Rita L.} and Edward Staab and Adler, {Lee P.} and Judy Lovelace and Perry Shen and John Stewart and Sergei Dolinsky",

year = "2005",

month = oct,

doi = "10.1016/j.amjsurg.2005.06.029",

language = "English",

volume = "190",

pages = "628--632",

journal = "American Journal of Surgery",

issn = "0002-9610",

publisher = "Elsevier Inc.",

number = "4",

}

Tafra, L, Cheng, Z, Uddo, J, Lobrano, MB, Stein, W, Berg, WA, Levine, E, Weinberg, IN, Narayanan, D, Ross, E, Beylin, D, Yarnall, S, Keen, R, Sawyer, K, Van Geffen, J, Freimanis, RL, Staab, E, Adler, LP, Lovelace, J, Shen, P, Stewart, J & Dolinsky, S 2005, 'Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer', American Journal of Surgery, vol. 190, no. 4, pp. 628-632. https://doi.org/10.1016/j.amjsurg.2005.06.029

TY - JOUR

T1 - Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer

AU - Tafra, Lorraine

AU - Cheng, Zandra

AU - Uddo, Joseph

AU - Lobrano, Mary B.

AU - Stein, William

AU - Berg, Wendie A.

AU - Levine, Edward

AU - Weinberg, Irving N.

AU - Narayanan, Deepa

AU - Ross, Eric

AU - Beylin, David

AU - Yarnall, Stephen

AU - Keen, Rochelle

AU - Sawyer, Kristen

AU - Van Geffen, Jack

AU - Freimanis, Rita L.

AU - Staab, Edward

AU - Adler, Lee P.

AU - Lovelace, Judy

AU - Shen, Perry

AU - Stewart, John

AU - Dolinsky, Sergei

PY - 2005/10

Y1 - 2005/10

N2 - Background: High-resolution positron-emission mammography (PEM) is a new device, which allows the imaging of breast tissue. A prospective study was performed to assess the accuracy of PEM in newly diagnosed breast cancer patients. Methods: In a prospective multicenter study, 44 women with confirmed breast cancers were imaged with a high-resolution PEM scanner (Naviscan PET Systems, Rockville, MD) with 18F-fluorodeoxyglucose. The images were blindly evaluated and were compared with final pathology. Results: The majority of the index lesions were seen on PEM (89%, 39/44). PEM detected 4 of 5 incidental breast cancers, 3 of which were not seen by any other imaging modalities. Of 19 patients undergoing breast-conserving surgery, PEM correctly predicted 6 of 8 (75%) patients with positive margins and 100% (11/11) with negative margins. Conclusion: The current PEM device shows promise in detecting breast malignancies and may assist in the planning of adequate partial mastectomy procedures to better ensure negative margins.

AB - Background: High-resolution positron-emission mammography (PEM) is a new device, which allows the imaging of breast tissue. A prospective study was performed to assess the accuracy of PEM in newly diagnosed breast cancer patients. Methods: In a prospective multicenter study, 44 women with confirmed breast cancers were imaged with a high-resolution PEM scanner (Naviscan PET Systems, Rockville, MD) with 18F-fluorodeoxyglucose. The images were blindly evaluated and were compared with final pathology. Results: The majority of the index lesions were seen on PEM (89%, 39/44). PEM detected 4 of 5 incidental breast cancers, 3 of which were not seen by any other imaging modalities. Of 19 patients undergoing breast-conserving surgery, PEM correctly predicted 6 of 8 (75%) patients with positive margins and 100% (11/11) with negative margins. Conclusion: The current PEM device shows promise in detecting breast malignancies and may assist in the planning of adequate partial mastectomy procedures to better ensure negative margins.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Breast Neoplasms/diagnostic imaging

KW - Female

KW - Fluorodeoxyglucose F18

KW - Humans

KW - Mammography/methods

KW - Middle Aged

KW - Pilot Projects

KW - Positron-Emission Tomography/methods

KW - Predictive Value of Tests

KW - Prospective Studies

KW - Radiopharmaceuticals

KW - Single-Blind Method

UR - http://www.scopus.com/inward/record.url?scp=24944511980&partnerID=8YFLogxK

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000232189600027&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.amjsurg.2005.06.029

DO - 10.1016/j.amjsurg.2005.06.029

M3 - Article

C2 - 16164937

SN - 0002-9610

VL - 190

SP - 628

EP - 632

JO - American Journal of Surgery

JF - American Journal of Surgery

IS - 4

ER -

Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this